Pricing Log in Create free account
Saturday 17 October 2026 Export EIGRQ’s income statement to Excel — free account

Eiger BioPharmaceuticals, Inc.

EIGRQ Healthcare Biotechnology

Eiger BioPharmaceuticals, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $15.8 million, up 17.0% from fiscal 2022. Revenue growth for three consecutive years, operating cash flow growth for three.

8.50 0.00 0.00%
Market cap
$2.6M
P/E
0.0×
Fwd P/E
−0.8×
Dividend yield
—
F-score
4/9
Altman Z
−24.53
Beneish M
−3.24
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 11.25%

Capital & Financial Ratios $m

Market Cap 2.55
Revenue 15.77
Net Income (74.96)
Free Cash Flow (74.78)
Net Debt 15.68
Current Ratio 0.71 (below 1: weak)
Debt/Equity (2.84) (negative: negative equity)
P/E ratio 0.00
Fwd P/E (0.80) (negative: loss-making)
P/S ratio 0.80
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 34.91% (at or above 15%: strong)
Next Y EPS Growth 68.84% (at or above 15%: strong)
Next Y revenue growth 52.79% (at or above 10%: strong)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 4.4×, against a ten-year median of 4.2×; over the ten years it ranged from −2.1× in 2022 to 20.6× in 2022.

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2020 2021 2022 2023
Cash 129 89 99 25
Receivables — 3 2 2
Inventory 0 3 3 2
Other — — — —
138 103 118 38
2020 2021 2022 2023
Payables 5 8 9 2
ST’ Debt 1 8 0 41
Other — — — —
17 30 25 53

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’23 4 5 3 4 16
’22 3 4 4 3 13
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’23 (24) (22) (15) (14) (75)
’22 (18) (22) (21) (22) (83)
’21 (15) (20) (19) (17) (71)
’20 (18) (16) (14) (16) (63)
’19 (19) (15) (15) (15) (64)
’18 (9) (8) (14) (13) (43)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’23 (24) (22) (15) (14) (75)
’22 (18) (22) (21) (22) (83)
’21 (15) (20) (19) (17) (72)
’20 (18) (16) (14) (16) (63)
’19 (19) (15) (15) (15) (64)
’18 (9) (8) (14) (13) (43)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’23 (15.62) (14.11) (12.31) (9.04) (50.78)
’22 (19.22) (15.31) (18.62) (17.12) (69.67)
’21 25.53 (17.12) (19.52) (19.22) (30.03)
’20 (18.62) (18.02) (15.62) (17.42) (69.37)
’19 (27.03) (22.52) (22.82) (20.72) (92.49)
’18 (25.22) (24.62) (36.04) (27.63) (114.71)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Trend 2024e 2025e 2026e
Price, $
Price, $ Low — — 321.30 183.00 223.80 281.40 136.50 150.30 28.80 6.00

Analyst estimates 2024–2026

Powerpack
High — — 774.00 435.00 540.00 474.60 453.60 404.70 300.64 89.40
People
People Employees — — 20 16 18 24 28 43 56 25
Revenue/emp, $m — — 0.00 0.00 0.00 0.00 0.00 0.28 0.24 0.63
Income, $m
Income, $m Revenue — — — — — — — 12 13 16
Gross margin, % — — 0.00 0.00 0.00 0.00 0.00 93.86 86.38 99.85
EBT — — (47) (42) (52) (70) (65) (34) (97) (75)
EBT margin, % — — 0.00 0.00 0.00 0.00 0.00 (278.81) (717.54) (475.22)
Net income — — (47) (42) (52) (70) (65) (34) (97) (75)
Depreciation — — 0 0 0 0 1 2 1 (1)
Per share, $
Per share, $ Revenue — — 0.00 0.00 0.00 0.00 0.00 10.74 9.71 10.69
Earnings — — (235.43) (145.95) (114.71) (92.49) (69.37) (30.03) (69.67) (50.78)
Cash flow — — (189.85) (132.04) (93.99) (83.83) (67.42) (63.12) (59.81) (50.51)
Capex — — (0.29) 0.54 (0.31) (0.63) (0.28) (0.20) (0.24) (0.16)
Free cash flow — — (190.14) (131.51) (94.30) (84.46) (67.69) (63.32) (60.05) (50.67)
Book value — — 203.61 77.50 146.68 74.43 101.40 64.05 39.85 (9.80)
Shares, m — — 0 0 0 1 1 1 1 1
Valuation, ×
Valuation, × P/E — — — — — — — 0.00 0.00 0.00
P/S — — — — — — — 14.49 3.83 0.66
P/B — — — — — — — 2.43 0.93 0.00
EV/Sales — — — — — — — 9.80 (0.53) 4.24
EV/FCF — — — — — — — (1.67) 0.09 (0.90)
Cash, $m
Cash, $m Operating cash flow — — (38) (38) (43) (64) (63) (71) (83) (75)
Capex — — 0 0 0 0 0 0 0 0
Free cash flow — — (38) (38) (43) (64) (63) (72) (83) (75)
Balance, $m
Balance, $m Working capital — — 55 35 92 83 121 73 92 (15)
Total debt — — 15 15 26 31 32 32 40 41
Net debt — — (45) (27) (75) (64) (97) (57) (59) 16
Shareholders’ equity — — 41 23 67 56 95 72 55 (14)
Returns, %
Returns, % ROA — — (142.00) (81.93) (72.10) (67.68) (52.31) (25.12) (78.51) (94.31)
ROIC — — 0.00 0.00 0.00 0.00 0.00 (312.68) 0.00 (3,674.55)
ROE — — (724.30) (134.24) (117.58) (114.16) (85.87) (40.51) (151.56) (367.00)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2023 · latest quarter Dec 2023

Charts ten years each

Eiger BioPharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SLXN Silexion Therapeutics Corp $2.7M — (loss-making) — — n/m −16.63% (below 0%: shrinking) — 0.00% Compare
GOVX GeoVax Labs Inc. $2.6M — (loss-making) — (loss-making) +183.44% (above 0%: growing) n/m +15.81% (above 0%: growing) 100.00% 0.00% Compare
XRTX XORTX Therapeutics Inc. $2.6M — (loss-making) — — n/m −318.40% (below 0%: shrinking) 0.00% 0.00% Compare
EIGRQ Eiger BioPharmaceuticals, Inc. $2.6M — (loss-making) — (loss-making) +41.06% (above 0%: growing) n/m +37.90% (above 0%: growing) 97.34% (331.69%)
BIORQ Biora Therapeutics, Inc. $2.5M — (loss-making) — (loss-making) +1,500.00% (above 0%: growing) n/m +20.72% (above 0%: growing) 100.00% (50,709.38%) Compare
ELAB PMGC Holdings Inc. $2.5M — (loss-making) — +147.70% (above 0%: growing) n/m −44.95% (below 0%: shrinking) 29.52% (292.91%) Compare
NTBLQ Notable Labs, Ltd. $2.4M — (loss-making) — (loss-making) −96.88% (below 0%: shrinking) n/m −26.63% (below 0%: shrinking) 100.00% (269,000.00%) Compare
VBIO Valion Bio, Inc. $2.4M — (loss-making) — (loss-making) +15.87% (above 0%: growing) n/m −189.01% (below 0%: shrinking) (99.32%) 0.00% Compare
MTNB Matinas Biopharma Holdings, Inc. $2.4M — (loss-making) — (loss-making) +365,433.33% (above 0%: growing) n/m +9.15% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $2.5M — — +165.57% — −21.63% 29.52% 0.00%

All 614 Biotechnology stocks →

Eiger BioPharmaceuticals, Inc. (EIGRQ) key facts

  • Strength: Eiger BioPharmaceuticals, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $15.8 million, up 17.0% from fiscal 2022.
  • Eiger BioPharmaceuticals, Inc. (EIGRQ) is a Biotechnology company in the Healthcare sector.
  • As of October 1, 2024, EIGRQ traded at $8.50, a market capitalization of $2.6 million.
  • Return on equity was −367.0% and debt-to-equity -2.84.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −24.53 (distress zone) for fiscal 2023.

Source: company filings (standardised) and stockrow calculations.

Eiger BioPharmaceuticals, Inc. (EIGRQ) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/EIGRQ · Data as of Dec 31, 2023 · For information only; not investment advice. · © 2026 stockrow.com